Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524136 | 0.90 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL3518699 | 0.90 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10030564 | 0.88 | SLC6A1 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL11395001 | 0.86 | NAAA (0.58) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL25022735 | 0.83 | NAAA (0.68) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL25022204 | 0.83 | NAAA (0.68) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL17377633 | 0.83 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL13285080 | 0.82 | CHRNB2 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL29542338 | 0.82 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL16528361 | 0.82 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | SLC6A1 350/4885SLC6A11 741/4885TSHR 1783/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | SLC6A1 350/4885SLC6A11 741/4885TSHR 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.